Savara Inc., a US-based clinical-level biopharmaceutical company focusing on rare respiratory diseases, has signed a $75 million royalty funding agreement with RTW Investments, LP, managing the funding process, which is entitled to FDA clearance of MOLBREEZI. The royalty financing will be effective on the FDA’s clearance of MOLBREEVI and relief of specific customary conditions.
According to the terms of the agreement, RTW will get a tiered single-digit percentage share of the annual net sales of MOLBREEVI in the U.S. for autoimmune PAP treatment titled to a CAP.
With this announcement, the J.D., MBA, Chair and chief executive officer at Savara, Matt Pauls, explained, “This smart, mindful financing will contribute to the US announced MOLBREEVI, expecting FDA approval, and will further enable us to invest in marketing priorities. We are on the right path to resubmit the MOLBREEVI BLA potential by this December. Following this, there’s no such approval for medicines in Europe and the US for autoimmune PAP.”
He further added, “We feel this drug will significantly change the way and perspective these chronic and rare diseases are treated. We’re excited and take this honour to work with RTW to introduce this fundamental therapy to the market.”
The MD, Mancheif investment officer and managing partner at RTW investments, LP, Roderick Wong, said, “The vital IMPALA-2 clinical trial elaborated the capability of MOLBREEVI to cure autoimmune PAP, and with recent investment, we gather and stand with the confidence we have in Savara and the robust marketing potential of the therapy. We are grateful to collaborate with the Savara management team, and further, we’re looking forward to contributing to their initiatives to reveal valuable treatment to patients.”
The autoimmune PAP is a rare lung disease defined by the abnormal build-up of surfactant in the alveoli of the lungs. The surfactant involves lipids and proteins. With this disease, patients might go through chest pain, coughing of blood and fever. This disease could lead to more severe complications in long-term cases, including the need for a lung transplant and lung fibrosis. This partnership, along with business benefit, will also contribute to the launch of MOLBREEVI in autoimmune pulmonary alveolar proteinosis (autoimmune PAP).
The collaboration will help to introduce or implement new solutions or drug development in the near future to bring valuable treatment to the autoimmune PAP patient population.
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
